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Abstract
Since the announcement of the STEP trial results in the past months, we have heard many sober
pronouncements on the possibility of an HIV vaccine. On the other hand, optimistic quotations
have been liberally used, from Shakespeare's Henry V's "Once more unto the breach, dear friends"
to Winston Churchill's definition of success as "going from one failure to another with no loss of
enthusiasm". I will forgo optimistic quotations for the phrase "Sang Froid", which translates literally
from the French as "cold blood"; what it really means is to avoid panic when things look bad, to
step back and coolly evaluate the situation. This is not to counsel easy optimism or to fly in face of
the facts, but I believe that while the situation is serious, it is not desperate.
I should stipulate at the outset that I am neither an immunologist nor an expert in HIV, but
someone who has spent his life in vaccine development. What I will try to do is to provide a point
of view from that experience.
There is no doubt that the results of STEP were disappointing: not only did the vaccine fail to
control viral load, but may have adversely affected susceptibility to infection. But HIV is not the only
vaccine to experience difficulties; what lessons can we glean from prior vaccine development?
Lessons from vaccinology
First, look at an uncomplicated example: the rubella vac-
cine. This is a live attenuated virus that was isolated in WI-
38 fetal fibroblasts during the 1962/63 rubella pandemic
and attenuated by low temperature passage in those same
cells [1]. By selection of clones replicating at low temper-
ature, we obtained a virus that consistently multiplied in
seronegative humans and that evoked both humoral and
mucosal immune responses that blocked superinfection
[2]. Why was it successful in giving immunity? Of course,
the answer is this: neutralizing antibodies to rubella
present in the serum and on the mucosa are correlates of
protection in preventing both nasopharyngeal implanta-
tion and subsequent viremia [3].
However, things are not always that easy. Take the para-
myxoviruses measles and respiratory syncytial virus (RSV)
as examples. Live measles virus has been a great success in
eliminating the disease, but in the early days there was
also a licensed killed measles vaccine. Unfortunately,
when vaccinated children were exposed to wild measles
they suffered an atypical disease that included severe pul-
monary, hepatic and dermatologic manifestations. Simi-
larly, a formalin inactivated RSV vaccine was tested in
infants, many of whom developed severe respiratory dis-
ease after subsequent natural infection with the virus [4].
The pathogenetic features of these adverse reactions were
similar [Table 1]. In both cases, the antibodies elicited had
either disappeared or were non-protective because
directed against the wrong protein, the T cell response was
Th2 biased and contributed to the pathology, and replica-
tion of wild virus was enhanced [5-8]. Although I will not
argue that this type of reaction could also explain the
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putative enhanced acquisition of HIV in the STEP and
Phambili trials, it at least illustrates the idea that in the
absence of functional antibodies, cellular immunity of the
wrong type can enhance, rather than diminish susceptibil-
ity.
Another type of misadventure happened with the first
licensed rotavirus vaccine. This was an orally adminis-
tered mixture of a simian rotavirus and reassortants of
human and simian rotaviruses in which the simian virus
contributed 10 of the 11 double-stranded RNA segments.
Although protective, it caused intussusception (intestinal
invagination) in approximately one in 10,000 vaccinees
[9]. This happened because the supposedly attenuated
simian vector retained pathogenicity for the infant intes-
tine, causing diarrhea and fever [10]. This problem was
solved in my former laboratory by substituting a bovine
rotavirus as vector, and in another lab, by classical attenu-
ation of a human rotavirus [11,12]. Neither of the new
vaccines causes intussusception [13,14]. The point is that
the choice of a supposedly attenuated vector is a key issue,
and that the wrong choice of vector brings safety prob-
lems.
Another lesson from vaccinology is that correlates of
immunity may be complex, and antibody and cellular
immunity are often collaborative. This point can be illus-
trated with reference to cytomegalovirus (CMV) [15,16].
As in HIV, superinfection may occur in previously infected
individuals, but the course of secondary infection is much
less pathogenic than in non-immune subjects. This is par-
ticularly important when infection occurs in pregnancy, as
the fetal outcomes after primary or secondary infection
are quite different.
Antibody against CMV alone may protect against primary
infection, but if infection occurs, cellular immunity is crit-
ical in controlling it. In addition, challenge dose is an
important variable, and can overcome moderate levels of
immunity, a fact that may apply to HIV. This was shown
by challenge studies in which seronegative volunteers
could be infected with 10 PFU of a low-passage CMV,
whereas naturally seropositive volunteers were protected
against 100 PFU, but could also be infected if the dose was
raised to 1000 PFU [17].
Nevertheless, two vaccines in development have shown
moderate ability to prevent or modify CMV infection.
One is based on a live attenuated virus, and one on a glyc-
oprotein that induces neutralizing antibody [17,18].
Thus, the fact that superinfection has been demonstrated
in some already HIV-infected people does not necessarily
rule out a role for immunity in controlling disease after
infection [19,20].
Another example is immunity to smallpox after vaccinia,
about which one can say that antibody is key: high titers
give sterile immunity. However, as antibody wanes, infec-
tion may occur, which CD8+ T cells must control. Anti-
body lasts forever after vaccination and CD4+ T cells last
almost forever, but CD8+ T cells disappear after about 20
years. Thus, although complete protection is temporary,
protection against severe disease is permanent [21].
The last agent I would like to discuss before turning to HIV
is hepatitis C. There are many similarities between the two
agents, including the rapid development of geographical
variation, with a 30% nucleotide difference between hep-
atitis C genotypes [22]. Although hepatitis C is a flavivi-
rus, it shares a number of properties with HIV, as shown
in Table 2.
Interestingly, patients who resolve acute hepatitis C infec-
tions have higher levels of neutralizing antibodies early in
infection than do those who go on to chronic infection
(Figure 1). As in the case of HIV, antibodies do not help
when they develop late in chronic infection [23]. The tar-
get of neutralizing antibodies is the E2 envelope protein,
and as in HIV, escape occurs [24,25].
However, it appears that late in the infection, induction or
reconstitution of cellular immune responses also corre-
lates with recovery from chronic hepatitis C viremia [26-
30]. Those cellular responses are mediated by both CD4+
and CD8+ T cells directed against non-structural as well as
structural proteins; to be effective, those responses must
Table 1: Severe reactions to Inactivated Measles and RSV Vaccines
Following exposure, vaccinees had exaggerated disease in lungs.
Pathology included immune complex deposition and high replication in the lungs.
Vaccines elicited non-protective, low avidity, waning antibodies.
Vaccines elicited strong CD4+ proliferation with a Th2 cytokine response, including IL-13
Caused cessation of use of both vaccinesJournal of the International AIDS Society 2009, 12:2 http://www.jiasociety.org/content/12/1/2
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be strong, highly avid, and directed against multiple
epitopes [31-34]. Although a crucial difference between
the two viruses is the lack of integration by hepatitis C in
contrast to HIV, I think it is instructive to see that a
chronic infection can be counteracted by standard
immune responses [32].
Innate immunity
So what can be said about immune protection against
HIV? With regard to innate immune responses, we know
that they are clearly valuable [35,36], both immediately
after infection and as adjuvants to adaptive immune
responses. The question is: do they have memory? A
Table 2: Similarities between Hepatitis C and HIV
HCV HIV
Envelope and Core Ags ++
Glycosylated envelope protein ++
Envelope is neut. target, but hypervariable ++
Chronic viremia ++
Escape mutation ++
Geographical genetic variation ++
PD-1 Upregulated ++
High titer neutralizing Ab protects ++
Strong cell responses against multiple epitopes necessary for control of viremia ++
CD4+ cells needed to sustain CD8+ T cells ++
Tcm cells needed for long-term control ++
Neutralizing antibodies in patients with resolved or chronic hepatitis C Figure 1
Neutralizing antibodies in patients with resolved or chronic hepatitis C.Journal of the International AIDS Society 2009, 12:2 http://www.jiasociety.org/content/12/1/2
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method of maintaining elevated innate immune
responses after immunization, particularly NK cells or
intracellular APOBEC3G, could be valuable, although
contrariwise after HIV infection, it has been reported that
an HIV-induced ligand is responsible for CD4+ T cell
destruction by NK cells [37].
On the other hand, a recent report [38] shows that the
gene Apobec3 encodes Rfv3, which enhances neutralizing
antibody responses against lentiviruses. This opens a new
avenue of research to counteract its antagonist, the Vif ele-
ment of HIV. In addition, soluble CD40 ligand has been
shown recently to enhance HIV-specific memory T cell
responses [39,40].
Antibodies
Clearly, everybody would like to know how to induce a
neutralizing response that covers primary isolates from all
of the clades. A recent list of approaches is shown in Table
3[41]. To this list may be added: the recent studies
attempting to mimic the b12-like antibodies produced by
some infected individuals [42]; studies using alloantigens
like hsp70 as part of an immunization regimen that
apparently evokes a wider breadth of neutralization [43];
and the use of AAV as a vector to carry an antibody-pro-
ducing gene into the cells of a vaccinee [44].
However, short of the ideal of broad neutralization with a
single antigen, it is not beyond our abilities to produce
multivalent vaccines. Because of multiple serotypes or
subtypes, numerous licensed vaccines are actually multi-
valent, including those for Human Papilloma, Influenza,
Meningococcal, Pneumococcal, Polio, and Rotavirus.
Moreover, every year we change the valences of influenza
vaccines to match the evolution of the virus. Although this
is not an ideal scenario, most years it works well; on con-
dition that surveillance is good, and that there are regional
manufacturers, it is practical to make different vaccines for
different areas.
Thus, although antibodies to conserve epitopes are highly
desirable, antibodies to gp120 loops that mutate and are
regional in distribution may require continuous updating
and regionalization of vaccine antigens (as for flu), as well
as the inclusion of multiple gp 120s. Even with break-
throughs in finding conserved epitopes, I doubt that we
can escape totally from having to make multivalent or
regional HIV vaccines [45]. Indeed, recent reports suggest
that multivalent HIV envelopes do give broad neutralizing
responses [46-49].
Does antibody protect against HIV infection? Clearly,
non-human primate studies using HIVIG or monoclonal
antibodies strongly support an affirmative answer [50-
53]. In addition, the burden of evidence is in favor of a
protective ability of maternal neutralizing antibodies in
prevention of HIV transmission to the newborn [54].
Moreover, it has been reported that neutralizing antibod-
ies develop rapidly and in high titer after HIV-2 infection,
which could explain the much slower disease progression
in HIV-2 patients [55-57].
How much antibody is needed for protection? A number
of estimates have been made, and these are summarized
in Table 4[50,52,58-61]. In addition, although superin-
fection is a fact in the presence of low levels of homolo-
gous neutralizing antibodies, there are data suggesting
high levels are protective [62]. So if high levels of antibody
are necessary for protection, in line with the need for mul-
tiple hits to neutralize the virion, and as HIV spreads from
the site of implantation within several days, effector B
cells must be in the circulation and producing antibody at
the time of exposure [63,64]. Thus, booster doses of an
AIDS vaccine will be necessary to maintain protective lev-
els of antibody.
Table 3: Novel approaches to the design of envelope immunogens
Mimic native trimer on virion surface
Redirect immune responses to conserved conformational epitopes
Add disulfides or other amino acids to stabilize conformational epitopes
Bind envelope to CD4 or CD4-mimetic peptide
Remove carbohydrate residue or entire carbohydrate side chains
Redirect responses away from variable epitopes
Remove one or more variable loops
Add carbohydrate side chains to hide
variable regionsJournal of the International AIDS Society 2009, 12:2 http://www.jiasociety.org/content/12/1/2
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Indeed, booster doses are commonly needed for vaccines,
even for some that are highly efficacious. They are almost
always needed for inactivated vaccines, e.g. tetanus, diph-
theria, and polysaccharide conjugates (exceptions are
hepatitis A and hepatitis B), and are often needed for live
vaccines, e.g. measles, mumps, and smallpox (exceptions
are rubella and OPV). This may be an inconvenient truth,
but the use of adjuvants might help prolong immunity.
The new adjuvants now available in vaccinology are
legion, and they increase breadth as well as height of anti-
body responses. They include oil-in-water and water-in-
oil emulsions, saponins, liposomes, lipopolysaccharides,
cytokines, cationic polymers for DNA plasmids, mast cell
activiators and numerous toll-like receptor (TLR) ago-
nists. A recent report showed that an oil-in-water emul-
sion containing monophosphoryl lipid A and QS-21
substantially increased the number of primary isolates
that could be neutralized in vitro by rabbit antisera
[45,65]. Much more work is needed in this area [66-68].
Cellular immunity
I think it is safe to say that cytotoxicity mediated by CD8+
T cells can for a time suppress HIV viral load, even if it can
not prevent acquisition of infection [69-79]. Clinical data
correlating CTL responses with control of viral load and
macaque studies by many labs have made that point
clearly. Two examples are illustrative: in Figure 2, CD8+ T
cells were clearly associated with low viral loads after chal-
lenge with SHIV [70]; and in a study of a DNA prime/ade-
novirus 5 boost, CTL against gag alone reduced viral load
after SIV challenge (Figure 3). Moreover, among many
other factors, elite HIV controllers, long-term non-pro-
gressors, and multiply exposed sex workers all have evi-
dence of potent CD8+ T cells in the blood and in the
mucosa [80-82], as well as innate immune factors [83].
However, there are issues of quantity. Recently, CTL
responses were measured after two conventional live vac-
cines, smallpox and yellow fever [84]. In terms of percent
CD8+ T cells specific to the vaccine, smallpox vaccine
induced about 10% vaccinia-specific cells producing IFN-
gamma, whereas yellow fever vaccine induced more than
2% yellow fever-specific cells. Compare those figures to
the data from the STEP study in which only 0.5 to 1% of
CD8+ T cells were specific to HIV (J McElrath, personal
communication, 2008). Thus, it is legitimate to ask
whether paucity of response played a role in the STEP fail-
ure.
Numerous factors influence the quality of CTL response,
some of which are listed in Table 5. Many groups have
demonstrated the importance of polyfunctionality, as
Table 4: Estimates of titers of neutralizing antibodies required for sterile protection against HIV.
Investigator Titer SN
End Point
Species Remarks
Trkola et al [58] 1/200 70% Human Acute infection
Parren et al [60] 1/400 90% Macaques SHIV Challenge
Nishimura et al. [61] 1/38 100% Macaques SHIV Challenge
Mascola et al [50,52] 1/50, 1/29–1/88 90% Macaques SHIV Challenge
Trkola et al [59] 1/400 90% Human Rebound after HAART
Control of High SHIV Viral Load by CD8+ Cells After Vacci- nation Figure 2
Control of High SHIV Viral Load by CD8+ Cells After 
Vaccination.Journal of the International AIDS Society 2009, 12:2 http://www.jiasociety.org/content/12/1/2
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defined by cytokine and chemokine secretion, in the con-
trol of HIV viral load [85-89] Other aspects of function
that are suggested to be important include: CTL avidity
[90,91]; number of epitopes seen by the CD8+ T cells
[90,92], which is a reason for exploring the use of consen-
sus and mosaic sequences to induce responses to more
epitopes [86,91,93,94]; presence of polyfunctional CD8s
in the rectal mucosa; preservation of Th17 cells [95]; and
persistence of both CD4+ and CD8+ central memory T
cells [92,96]. As it is likely that semen of HIV-transmitting
patients will have both cell-free and cell-associated virus,
it appears necessary that the CD8+ T cells be capable of
killing infected cells in the inoculum [97].
My goal here is not to exhaustively examine all of the
important T cell responses, but rather to say that there are
numerous leads with regard to improving cellular
immune responses to an HIV vaccine, and that the failure
of the first trial of this idea says only that the responses
induced were inadequate to simulate those induced dur-
ing natural infection that appear to control HIV temporar-
ily.
Mucosal immunity
It has become a cliché to say that vaccines can not provide
sterile immunity. In my view, this is a canard. As indicated
in Table 6, if the pathogenic agent is injected into the
blood stream, as in arbovirus infection, or acts by a toxin,
as in tetanus, sterile immunity is undoubted. In addition,
if the agent implants first on the mucosa, as in many infec-
tions, sterile immunity is achievable on condition that
mucosal immunity is sufficient to abort that replication.
Examples of this principle include resistance to measles
and rubella after vaccination with live viruses that induce
both serum and mucosal antibody [21,98], and live or
killed influenza vaccines, after which induction of either
serum or mucosal antibody can completely prevent infec-
tion [99].
Mucosal immunity is as complex as systemic immunity
[100-104]. Secretory IgA may neutralize on the surface or
Control of High SIV Viral Load by cellular Responses to DNA/Adeno Vaccination Figure 3
Control of High SIV Viral Load by cellular Responses to DNA/Adeno Vaccination.
Table 5: Cellular immune responses to HIV that could be 
improved
Quantity of specific CD8+ cells
Polyfunctionality of CD8+ cells
Avidity of CD8+ cells
Number of epitopes seen
Intestinal homing of CD8+ cells
Th17/Tregs balance
Increased CD4+ central memory cells
Increased CD8+ central memory cellsJournal of the International AIDS Society 2009, 12:2 http://www.jiasociety.org/content/12/1/2
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block transcytosis [105]. Second, the CTL population in
the intestine is numerous and can kill HIV-infected cells,
which is important in view of the evidence that preserva-
tion of intestinal memory CD4+ T cells contributes to a
good prognosis for the subsequent course of HIV infec-
tion [106,107]. Third, serum IgG can diffuse onto
mucosal surfaces, particularly in the respiratory tract. The
latter fact probably accounts for the reduction of pharyn-
geal carriage of encapsulated bacteria by conjugated
polysaccharide vaccines, and the reduction of virus titer in
the pharynx and stool of IPV vaccinees [21,102].
I alluded to the live, orally administered rotavirus vaccine
previously, and there is another lesson to be learned from
the rotavirus story: rotavirus diarrhea is caused by replica-
tion of the virus in intestinal cells. There are three impor-
tant proteins of the virus: two of these, vp4 and vp7,
induce neutralizing antibodies, whereas the third, vp6,
induces non-neutralizing antibodies and cellular immune
responses.
With regard to the correlates of immunity, efficacy studies
show that type-specific neutralizing antibodies are an
important factor in protection. However, studies of natu-
ral immunity show that non-neutralizing as well as neu-
tralizing antibodies to vp6 also correlate with protection
[108,109]. Moreover, studies in animals demonstrate that
CTL in the intestinal lining against vp6 also have a role
[110]. Finally, measurement of serum IgA antibodies pro-
vide a surrogate of protection by the vaccine [111], indi-
cating that secretory IgA in the intestinal mucosa plays a
major role in that protection [112].
Thus, mucosal immunity collaborates with other func-
tions to control rotavirus, a theme reflected in studies of
macaques and of Kenyan sex workers (Figure 4), in whom
systemic T cell proliferation and neutralizing antibodies at
the level of the genital and intestinal tracts were synergis-
tic in protection against HIV [113,114].
Obviously, there are many problems to solve in attempt-
ing mucosal immunization. One approach is to mix
routes of administration, for example priming with oral
vaccination and following with parenteral boost. Moreo-
ver, it is not impossible to consider mixed intranasal and
intrarectal administration to immunize both the genital
and gastrointestinal tract. Aerosol administration of HPV
vaccine has been reported to induce IgA secreting cells in
the genital tract [115], and there is recent work suggesting
that sublingual administration of antigens may be a way
around compartmentalization of mucosal immunity
[116] (see table 7).
The future
Of course, we must look at new vectors [117-122]. Repli-
cating adenovirus vectors boosted by viral proteins have
given promising results in prevention of SIV infection in
macaques [123-125]. An interesting observation made in
those studies and in other studies in macaques is the pro-
tection afforded by non-neutralizing antibodies through
their action on infected cells by mechanisms such as
ADCC [126-128]. This echoes the theme mentioned in
relation to rotavirus.
Cytomegalovirus is under test as a replicating vector, as
are measles, Sendai viruses and VSV [129,130]. DNA plas-
mids are enjoying a renaissance thanks to the concomi-
tant use of electroporation and new adjuvants
[49,131,132]. In addition, the European Consortium, has
Acquisition of HIV by Kenyan Sex Workers Prevented by  Genital IgA and Systemic T Cell Proliferation Figure 4
Acquisition of HIV by Kenyan Sex Workers Pre-
vented by Genital IgA and Systemic T Cell Prolifera-
tion. Obviously, there are many problems to solve in 
attempting mucosal immunization. One approach is to mix 
routes of administration, for example priming with oral vacci-
nation and following with parenteral boost. Moreover, it is 
not impossible to consider mixed intranasal and intrarectal 
administration to immunize both the genital and gastrointes-
tinal tract. Aerosol administration of HPV vaccine has been 
reported to induce IgA secreting cells in the genital tract 
[115], and there is recent work suggesting that sublingual 
administration of antigens may be a way around compart-
mentalization of mucosal immunity [116] (see table 7).
Table 6: Do vaccines elicit "sterile" immunity?
Yes Depends Mucosal Presence of Antibody
Diphtheria Polio
Hepatitis A Hib
Hepatitis B Influenza
Lyme Measles
Rabies Pertussis
Tetanus Rubella
Yellow Fever VaricellaJournal of the International AIDS Society 2009, 12:2 http://www.jiasociety.org/content/12/1/2
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reported polyfunctional T cell responses in humans after
a DNA-NYVAC vaccinia regimen [133]. Non-parenteral
routes of administration of non-replicating vectors are
also being explored [134]. Transfer of the gene for a neu-
tralizing antibody via an adeno-associated virus vector to
vaccinees is another intriguing approach [44]. Homology
of anti-phospholipid antibodies and HIV epitopes is
being explored [135]. And some of our hearts still belong
to live attenuated HIV [136-138], although this is a con-
tentious area owing to safety concerns. One should also
keep in mind that the canarypox prime, gp120 boost trial
in Thailand has survived analyses for the futility of efficacy
and will be reported this year, and that the prime-boost
concept using a DNA prime and Ad5 boost, which gives
enhanced immune responses in comparison with Ad5
alone, remains to be tested in the clinic [139].
In summary, I believe that an effective HIV vaccine will
need to stimulate neutralizing antibodies, as well as CD4+
and CD8+ cellular responses in the blood and on the
mucosa. This is hardly a novel conclusion, and it is a tall
order, but the biology of the virus and the history of vac-
cinology tell us, respectively, that those responses are nec-
essary and that they have been feasible to induce for
previous vaccines.
At the beginning of this article, I disdained the use of opti-
mistic or pessimistic quotations to justify opinions about
the future of HIV vaccine development. I have tried to be
realistic in my own assessment of the situation and I will
close with one quotation, because it is definitely realistic,
as everyone who has ever worked in a laboratory knows.
It comes from Emile Roux, the associate of Pasteur and a
brilliant scientist in his own right. He said, "Science
appears calm and triumphant when it is completed; but
science in the process of being done is only contradiction
and torment, hope and disappointment." Let us not give
up, for as Roux would agree, the goal is worth it.
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